Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | CCR2 | P41597 | 12/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 3/20 | 0.44 |
| ▸ | HTR7 | P34969 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5353346 | 0.83 | KMT2A (0.58) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL5705116 | 0.81 | KDM4E (0.78) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL5266659 | 0.76 | CCR2 (0.70) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL5358767 | 0.74 | KMT2A (0.57) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL5327055 | 0.74 | KDM4E (0.56) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL5323484 | 0.73 | KMT2A (0.61) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL5358772 | 0.73 | KMT2A (0.58) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL5355885 | 0.72 | KMT2A (0.51) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL2841057 | 0.72 | KDM4E (0.59) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL27201572 | 0.71 | HSD11B1 (0.64) | KDM4EBRD4ALDH1A1POLBCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTCA N.V. (BE) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | CCR2, CCR1, CCR5 | KDM4E 3992/4885BRD4 235/4885ALDH1A1 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.